Skip to main content
Clinical Trials/NCT03557879
NCT03557879
Unknown
N/A

Exome Analysis on Hearing Impaired Patients

University Hospital, Montpellier1 site in 1 country30 target enrollmentJune 4, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hearing Impairment
Sponsor
University Hospital, Montpellier
Enrollment
30
Locations
1
Primary Endpoint
identification of candidate genes
Last Updated
7 years ago

Overview

Brief Summary

Hearing impairment is the most frequent sensory deficit in humans and affects one newborn out of 500. The prevalence rises to 3,5/1000 in teenagers due to retarded forms. Most of hearing impairments (about two thirds) have a genetic origin, with recessive, dominant or X-linked mode of inheritance. Some rare forms can be linked to mitochondrial DNA. Molecular diagnosis (i.e. defining the molecular basis of the disease, genes and precise DNA variants) is essential for the follow-up of patients and families.

The project intends to perform exome sequencing on 30 samples of families presenting with hearing impairment. Families have been included based on the genetic origin of the hearing impairment (familial cases) and the exclusion of the involvement of 74 known deafness genes. Exome sequencing (sequencing of the coding regions of all known genes, about 22,000) in these cases may underly new gene/disease relationships.

Detailed Description

Exome sequencing will be performed of 10 trios that each include two affected and one non affected members of a family. Filtering of variants will be performed based on frequency. For each trio, data will be analysed in parallel to follow segregation of the variant(s) in candidate genes. The selected candidate genes will be further characterized in order to ascertain their involvement in hearing function. Finally, once these new genes are well defined as "deafness genes" , their screening will be added to existing diagnostic panels.

Registry
clinicaltrials.gov
Start Date
June 4, 2018
End Date
June 1, 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype)
  • Exclusion criteria:
  • sporadic cases of hearing impairment, or resolved familial cases

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

identification of candidate genes

Time Frame: 1 day

Description: a candidate gene would present a genotype (combination of DNA variants) compatible with the transmission mode and several lines of evidence of the pathogenic effect of the DNA variants

Secondary Outcomes

  • Quality assessment of the exome sequencing(1 day)
  • Quality assessment of the bioinformatics pipelines used(1 day)

Study Sites (1)

Loading locations...

Similar Trials